Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?
- 1 March 2013
- journal article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 8 (3), 366-368
- https://doi.org/10.1097/jto.0b013e31827e2145
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2012
- Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trialThe Lancet, 2011
- Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancerCancer, 2007
- Adjuvant Therapy in the Elderly: Making the Right DecisionJournal of Clinical Oncology, 2007
- Phase III Study of Docetaxel Compared With Vinorelbine in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)Journal of Clinical Oncology, 2006
- Prospective Evaluation of the Relationship of Patient Age and Paclitaxel Clinical Pharmacology: Cancer and Leukemia Group B (CALGB 9762)Journal of Clinical Oncology, 2006
- The ELVIS Trial: A Phase III Study of Single-Agent Vinorelbine as First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung CancerThe Oncologist, 2001
- Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2000
- Age and cytochrome P450-linked drug metabolism in humans: An analysis of 226 subjects with equal histopathologic conditions*Clinical Pharmacology & Therapeutics, 1997
- Longitudinal Studies on the Rate of Decline in Renal Function with AgeJournal of the American Geriatrics Society, 1985